Cargando…

Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia

The International Prognostic Score of thrombosis in Essential Thrombocythemia (IPSET-thrombosis) and its revised version have been proposed to guide thrombosis prevention strategies. We evaluated both classifications to prognosticate thrombosis in 1366 contemporary essential thrombocythemia (ET) pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Alvarez-Larrán, Alberto, Cuevas, Beatriz, Velez, Patricia, Noya, Soledad, Caballero-Navarro, Gonzalo, Ferrer-Marín, Francisca, Carbonell, Sara, Pérez-Encinas, Manuel, Gómez-Casares, María Teresa, Pérez-López, Raúl, Magro, Elena, Moretó, Ana, Pastor-Galán, Irene, Angona, Anna, Mata-Vázquez, María Isabel, Guerrero-Fernández, Lucía, Guerra, José María, Carreño-Tarragona, Gonzalo, Fox, Laura, Murillo, Ilda, García-Gutiérrez, Valentín, Mora, Elvira, Stuckey, Ruth, Arellano-Rodrigo, Eduardo, Hernández-Boluda, Juan Carlos, Pereira, Arturo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356121/
https://www.ncbi.nlm.nih.gov/pubmed/37476303
http://dx.doi.org/10.1097/HS9.0000000000000936
_version_ 1785075201809055744
author Alvarez-Larrán, Alberto
Cuevas, Beatriz
Velez, Patricia
Noya, Soledad
Caballero-Navarro, Gonzalo
Ferrer-Marín, Francisca
Carbonell, Sara
Pérez-Encinas, Manuel
Gómez-Casares, María Teresa
Pérez-López, Raúl
Magro, Elena
Moretó, Ana
Pastor-Galán, Irene
Angona, Anna
Mata-Vázquez, María Isabel
Guerrero-Fernández, Lucía
Guerra, José María
Carreño-Tarragona, Gonzalo
Fox, Laura
Murillo, Ilda
García-Gutiérrez, Valentín
Mora, Elvira
Stuckey, Ruth
Arellano-Rodrigo, Eduardo
Hernández-Boluda, Juan Carlos
Pereira, Arturo
author_facet Alvarez-Larrán, Alberto
Cuevas, Beatriz
Velez, Patricia
Noya, Soledad
Caballero-Navarro, Gonzalo
Ferrer-Marín, Francisca
Carbonell, Sara
Pérez-Encinas, Manuel
Gómez-Casares, María Teresa
Pérez-López, Raúl
Magro, Elena
Moretó, Ana
Pastor-Galán, Irene
Angona, Anna
Mata-Vázquez, María Isabel
Guerrero-Fernández, Lucía
Guerra, José María
Carreño-Tarragona, Gonzalo
Fox, Laura
Murillo, Ilda
García-Gutiérrez, Valentín
Mora, Elvira
Stuckey, Ruth
Arellano-Rodrigo, Eduardo
Hernández-Boluda, Juan Carlos
Pereira, Arturo
author_sort Alvarez-Larrán, Alberto
collection PubMed
description The International Prognostic Score of thrombosis in Essential Thrombocythemia (IPSET-thrombosis) and its revised version have been proposed to guide thrombosis prevention strategies. We evaluated both classifications to prognosticate thrombosis in 1366 contemporary essential thrombocythemia (ET) patients prospectively followed from the Spanish Registry of ET. The cumulative incidence of thrombosis at 10 years, taking death as a competing risk, was 11.4%. The risk of thrombosis was significantly higher in the high-risk IPSET-thrombosis and high-risk revised IPSET-thrombosis, but no differences were observed among the lower risk categories. Patients allocated in high-risk IPSET-thrombosis (subdistribution hazard ratios [SHR], 3.7 [95% confidence interval, CI, 1.6-8.7]) and high-risk revised IPSET-thrombosis (SHR, 3.2 [95% CI, 1.4-7.45]) showed an increased risk of arterial thrombosis, whereas both scoring systems failed to predict venous thrombosis. The incidence rate of thrombosis in intermediate risk revised IPSET-thrombosis (aged >60 years, JAK2-negative, and no history of thrombosis) was very low regardless of the treatment administered (0.9% and 0% per year with and without cytoreduction, respectively). Dynamic application of the revised IPSET-thrombosis showed a low rate of thrombosis when patients without history of prior thrombosis switched to a higher risk category after reaching 60 years of age. In conclusion, IPSET-thrombosis scores are useful for identifying patients at high risk of arterial thrombosis, whereas they fail to predict venous thrombosis. Controlled studies are needed to determine the appropriate treatment of ET patients assigned to the non-high-risk categories.
format Online
Article
Text
id pubmed-10356121
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-103561212023-07-20 Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia Alvarez-Larrán, Alberto Cuevas, Beatriz Velez, Patricia Noya, Soledad Caballero-Navarro, Gonzalo Ferrer-Marín, Francisca Carbonell, Sara Pérez-Encinas, Manuel Gómez-Casares, María Teresa Pérez-López, Raúl Magro, Elena Moretó, Ana Pastor-Galán, Irene Angona, Anna Mata-Vázquez, María Isabel Guerrero-Fernández, Lucía Guerra, José María Carreño-Tarragona, Gonzalo Fox, Laura Murillo, Ilda García-Gutiérrez, Valentín Mora, Elvira Stuckey, Ruth Arellano-Rodrigo, Eduardo Hernández-Boluda, Juan Carlos Pereira, Arturo Hemasphere Article The International Prognostic Score of thrombosis in Essential Thrombocythemia (IPSET-thrombosis) and its revised version have been proposed to guide thrombosis prevention strategies. We evaluated both classifications to prognosticate thrombosis in 1366 contemporary essential thrombocythemia (ET) patients prospectively followed from the Spanish Registry of ET. The cumulative incidence of thrombosis at 10 years, taking death as a competing risk, was 11.4%. The risk of thrombosis was significantly higher in the high-risk IPSET-thrombosis and high-risk revised IPSET-thrombosis, but no differences were observed among the lower risk categories. Patients allocated in high-risk IPSET-thrombosis (subdistribution hazard ratios [SHR], 3.7 [95% confidence interval, CI, 1.6-8.7]) and high-risk revised IPSET-thrombosis (SHR, 3.2 [95% CI, 1.4-7.45]) showed an increased risk of arterial thrombosis, whereas both scoring systems failed to predict venous thrombosis. The incidence rate of thrombosis in intermediate risk revised IPSET-thrombosis (aged >60 years, JAK2-negative, and no history of thrombosis) was very low regardless of the treatment administered (0.9% and 0% per year with and without cytoreduction, respectively). Dynamic application of the revised IPSET-thrombosis showed a low rate of thrombosis when patients without history of prior thrombosis switched to a higher risk category after reaching 60 years of age. In conclusion, IPSET-thrombosis scores are useful for identifying patients at high risk of arterial thrombosis, whereas they fail to predict venous thrombosis. Controlled studies are needed to determine the appropriate treatment of ET patients assigned to the non-high-risk categories. Lippincott Williams & Wilkins 2023-07-18 /pmc/articles/PMC10356121/ /pubmed/37476303 http://dx.doi.org/10.1097/HS9.0000000000000936 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Alvarez-Larrán, Alberto
Cuevas, Beatriz
Velez, Patricia
Noya, Soledad
Caballero-Navarro, Gonzalo
Ferrer-Marín, Francisca
Carbonell, Sara
Pérez-Encinas, Manuel
Gómez-Casares, María Teresa
Pérez-López, Raúl
Magro, Elena
Moretó, Ana
Pastor-Galán, Irene
Angona, Anna
Mata-Vázquez, María Isabel
Guerrero-Fernández, Lucía
Guerra, José María
Carreño-Tarragona, Gonzalo
Fox, Laura
Murillo, Ilda
García-Gutiérrez, Valentín
Mora, Elvira
Stuckey, Ruth
Arellano-Rodrigo, Eduardo
Hernández-Boluda, Juan Carlos
Pereira, Arturo
Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia
title Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia
title_full Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia
title_fullStr Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia
title_full_unstemmed Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia
title_short Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia
title_sort application of ipset-thrombosis in 1366 patients prospectively followed from the spanish registry of essential thrombocythemia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356121/
https://www.ncbi.nlm.nih.gov/pubmed/37476303
http://dx.doi.org/10.1097/HS9.0000000000000936
work_keys_str_mv AT alvarezlarranalberto applicationofipsetthrombosisin1366patientsprospectivelyfollowedfromthespanishregistryofessentialthrombocythemia
AT cuevasbeatriz applicationofipsetthrombosisin1366patientsprospectivelyfollowedfromthespanishregistryofessentialthrombocythemia
AT velezpatricia applicationofipsetthrombosisin1366patientsprospectivelyfollowedfromthespanishregistryofessentialthrombocythemia
AT noyasoledad applicationofipsetthrombosisin1366patientsprospectivelyfollowedfromthespanishregistryofessentialthrombocythemia
AT caballeronavarrogonzalo applicationofipsetthrombosisin1366patientsprospectivelyfollowedfromthespanishregistryofessentialthrombocythemia
AT ferrermarinfrancisca applicationofipsetthrombosisin1366patientsprospectivelyfollowedfromthespanishregistryofessentialthrombocythemia
AT carbonellsara applicationofipsetthrombosisin1366patientsprospectivelyfollowedfromthespanishregistryofessentialthrombocythemia
AT perezencinasmanuel applicationofipsetthrombosisin1366patientsprospectivelyfollowedfromthespanishregistryofessentialthrombocythemia
AT gomezcasaresmariateresa applicationofipsetthrombosisin1366patientsprospectivelyfollowedfromthespanishregistryofessentialthrombocythemia
AT perezlopezraul applicationofipsetthrombosisin1366patientsprospectivelyfollowedfromthespanishregistryofessentialthrombocythemia
AT magroelena applicationofipsetthrombosisin1366patientsprospectivelyfollowedfromthespanishregistryofessentialthrombocythemia
AT moretoana applicationofipsetthrombosisin1366patientsprospectivelyfollowedfromthespanishregistryofessentialthrombocythemia
AT pastorgalanirene applicationofipsetthrombosisin1366patientsprospectivelyfollowedfromthespanishregistryofessentialthrombocythemia
AT angonaanna applicationofipsetthrombosisin1366patientsprospectivelyfollowedfromthespanishregistryofessentialthrombocythemia
AT matavazquezmariaisabel applicationofipsetthrombosisin1366patientsprospectivelyfollowedfromthespanishregistryofessentialthrombocythemia
AT guerrerofernandezlucia applicationofipsetthrombosisin1366patientsprospectivelyfollowedfromthespanishregistryofessentialthrombocythemia
AT guerrajosemaria applicationofipsetthrombosisin1366patientsprospectivelyfollowedfromthespanishregistryofessentialthrombocythemia
AT carrenotarragonagonzalo applicationofipsetthrombosisin1366patientsprospectivelyfollowedfromthespanishregistryofessentialthrombocythemia
AT foxlaura applicationofipsetthrombosisin1366patientsprospectivelyfollowedfromthespanishregistryofessentialthrombocythemia
AT murilloilda applicationofipsetthrombosisin1366patientsprospectivelyfollowedfromthespanishregistryofessentialthrombocythemia
AT garciagutierrezvalentin applicationofipsetthrombosisin1366patientsprospectivelyfollowedfromthespanishregistryofessentialthrombocythemia
AT moraelvira applicationofipsetthrombosisin1366patientsprospectivelyfollowedfromthespanishregistryofessentialthrombocythemia
AT stuckeyruth applicationofipsetthrombosisin1366patientsprospectivelyfollowedfromthespanishregistryofessentialthrombocythemia
AT arellanorodrigoeduardo applicationofipsetthrombosisin1366patientsprospectivelyfollowedfromthespanishregistryofessentialthrombocythemia
AT hernandezboludajuancarlos applicationofipsetthrombosisin1366patientsprospectivelyfollowedfromthespanishregistryofessentialthrombocythemia
AT pereiraarturo applicationofipsetthrombosisin1366patientsprospectivelyfollowedfromthespanishregistryofessentialthrombocythemia